Fig. 1 · Structure

Documents & Downloads

Imatinib Mesylate

Cat. No. A10468 CAS 220127-57-1

Bcr-Abl inhibitor

Imatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway.

In Stock

Publications for Imatinib Mesylate

2 publications citing this product

  1. Inge Govaerts, .et al. , J Hematol Oncol, 2021, 14: 97 PMID: 34167562
  2. Genevra Kuziel, .et al. , Cancers (Basel), 2020, Jul 28;12(8):E2083 PMID: 32731354

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Structural studies show that the imatinib active moiety binds the ATP-binding region of Abl and stabilizes an inactive activation-loop conformation. This evidence concerns synthesized imatinib; it does not establish salt-specific potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PDGFR (Cell-free assay) 100 nM
c-Kit (M-07e cells) 100 nM
v-Abl (Cell-free assay) 600 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 1.87 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by xCELLigence RTCA [PMID: 32866755]
Bel-7402 IC50 55.52 μM Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 48 hrs by xCELLigence RTCA [PMID: 32866755]
GIST882 IC50 1.7 μM Growth inhibition of human GIST882 cells expressing c-Kit after 96 hrs by SRB assay [PMID: 24900212]
K562 IC50 0.21 μM Cytotoxicity against human K562 cells after 24 hrs by MTT assay [PMID: 22000207]
K562 IC50 0.31 μM Cytotoxicity against human K562 cells measured after 72 hrs by MTT assay [PMID: 28075592]
KBM5 IC50 152.2 nM Cytotoxicity against Imatinib mesylate sensitive wild-type human KBM5 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 34052717]
KBM5 IC50 310.6 nM Cytotoxicity against imatinib mesylate resistant wild-type human KBM5 cells expressing T315I mutant assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 34052717]
KU812 cell line EC50 0.6 μM Cytotoxicity against human KU812 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 29778892]
KU812 cell line IC50 311.2 nM Cytotoxicity against Bcr-Abl expressing human KU812 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 34052717]
LAMA-84 IC50 100 nM Antiproliferative activity against human LAMA-84 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay [PMID: 28523104]
MCF7 IC50 0.83 μM Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay [PMID: 22000207]
MDA-MB-231 IC50 1.8 μM Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay [PMID: 22000207]
MKN-45 IC50 12.18 μM Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability incubated for 48 hrs by xCELLigence RTCA [PMID: 32866755]
SGC-7901 IC50 0.208 μM Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability incubated for 48 hrs by xCELLigence RTCA [PMID: 32866755]
Vero C1008 CC50 > 30.86 μM CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells 10.1101/2020.03.25.008482
Vero C1008 CC50 > 30.86 μM CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells 10.1101/2020.03.25.008482
Vero C1008 IC50 3.24 μM IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells 10.1101/2020.03.25.008482
Vero C1008 IC50 5.32 μM IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells 10.1101/2020.03.25.008482

18 records · Scroll to view more

Imatinib Mesylate Research Summary

This section summarizes 4 in vitro studies of Imatinib Mesylate from 3 published references. In vitro models include ALL-SIL T-ALL cells.

Imatinib Mesylate In Vitro Studies

In NUP214-ABL1-positive ALL-SIL cells, imatinib plus MRK-560 reduced cell accumulation more than either agent alone. Separate pretreatment assays showed an enhanced imatinib response and a synergistic interaction. The long-term combination effect was not reproduced in RPMI-8402 or LOUCY comparator cells. [2]

In cultured mouse mammary CD11b+ cells, imatinib mesylate reduced fibrocyte colony number and size over 10 days. This colony endpoint does not identify whether proliferation or survival was primarily affected, and it does not establish an exclusive PDGFRα mechanism. [3]

Imatinib binding to the inactive Abl kinase domain

Biochemical assay · Unphosphorylated murine c-Abl kinase domain (residues 229–515); crystallographic comparator PD173955 [1]

The intact inhibitor occupies the ATP-binding region and stabilizes an inactive activation-loop conformation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Abl–STI-571 diffraction resolutionresolution 2.1 Å[1]
Binding conformationstructural observation ATP-binding region occupied; inactive activation loop[1]

Literature-Reported Treatment Conditions

Method
X-ray crystallography
Vehicle
DMSO used for inhibitor dissolution
Reported limits
Counterion not specified; crystallographic binding is not an IC50 or cellular efficacy assay.
Methods and source locations

Compound reported in the paper: Imatinib; Compound label in the paper: STI-571

Active-moiety structural mechanism; no salt-specific potency.

pp. 4237–4239; Table 1; Figs. 1a and 3A–B

Abl–STI-571 diffraction resolution: X-ray crystallography — p. 4237, Table 1; p. 4238, Overall Features of the Structures

Binding conformation: Refined structure, PDB 1IEP — pp. 4238–4239, Structure of Abl Kinase Domain Bound to STI-571; Fig. 3A–B

Long-term ALL-SIL proliferation with imatinib and MRK-560

Cell-based study · ALL-SIL T-ALL cells carrying NUP214-ABL1; RPMI-8402 and LOUCY comparator cell lines [2]

Combined treatment reduced ALL-SIL cell accumulation more than either single treatment. Comparator lines did not show the same combination response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Absolute cell accumulation over timequalitative Greater reduction with combination in ALL-SIL; no comparable combination response in RPMI-8402 or LOUCY[2]

Literature-Reported Treatment Conditions

Treatment concentration
Imatinib 10 nM; MRK-560 100 nM
Exposure duration
14 days
Method
Serial cell counts by flow cytometry; fresh medium and compounds every 2–3 days
Vehicle
DMSO
Co-treatment
MRK-560 100 nM; single-agent and DMSO groups included
Reported limits
Vehicle percentage not specified for this experiment.
Methods and source locations

Compound reported in the paper: Imatinib mesylate; Compound label in the paper: Imatinib

Reported research material in this experiment; no current-lot identity, purity or performance validation.

Fig. 2g and caption; Results, MRK-560 combination with kinase inhibitors; Methods, Proliferation assays

Absolute cell accumulation over time: Flow cytometric counts; biological triplicates; mean ± SD — Fig. 2g; accompanying Results paragraph

MRK-560 pretreatment enhances the imatinib response in ALL-SIL

Cell-based study · ALL-SIL T-ALL cells [2]

Seven-day MRK-560 pretreatment increased the response to subsequent imatinib. The authors classified the combination as synergistic using the Chou–Talalay method.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative cell number and combination interactionqualitative Enhanced response after MRK-560 pretreatment; synergistic interaction reported[2]

Literature-Reported Treatment Conditions

Treatment concentration
MRK-560 pretreatment 0.1 or 1 µM; imatinib 0, 2.5, 5 or 10 nM in Fig. 2h
Exposure duration
7-day pretreatment followed by 48-hour assay
Method
ATPlite proliferation endpoint; CompuSyn combination-index analysis
Vehicle
DMSO; compound concentrations normalized to DMSO
Co-treatment
MRK-560 pretreatment followed by imatinib; DMSO pretreatment control
Reported limits
Individual numeric combination indices are not tabulated in the adopted evidence; no exact curve values extracted.
Methods and source locations

Compound reported in the paper: Imatinib mesylate; Compound label in the paper: Imatinib

Reported research material in this experiment; no current-lot identity, purity or performance validation.

Fig. 2h–i and caption; Methods, Proliferation assays and statistical analyses

Relative cell number and combination interaction: ATPlite; biological triplicates in Fig. 2h; Chou–Talalay combination index in Fig. 2i — Fig. 2h–i and accompanying Results

Imatinib reduces mammary fibrocyte colony formation

Cell-based study · Mouse mammary-gland CD11b+ cells isolated by magnetic beads and cultured for fibrocyte colony formation [3]

Imatinib reduced colony number and colony size with increasing concentration. The endpoint does not distinguish reduced proliferation from increased apoptosis or establish exclusive PDGFRα causality.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fibrocyte colony number and sizequalitative Both decreased dose-dependently[3]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10 or 20 µM
Exposure duration
10 days; medium/treatment renewed on day 5
Method
Crystal-violet staining and ImageJ quantification of colony number and size
Vehicle
PBS control specified in Methods 4.6
Reported limits
Lot and purity not reported; specific cellular mechanism of colony loss not determined.
Methods and source locations

Compound reported in the paper: Imatinib mesylate; Compound label in the paper: Imatinib

Reported research material in this experiment; no current-lot identity, purity or performance validation.

Results 2.5; Fig. 5D–F; Methods 4.6 and 4.9

Fibrocyte colony number and size: n = 3 mice/treatment group as captioned; cultures grown in triplicate; colony number: one-way ANOVA/Tukey; colony size: Kruskal–Wallis/Dunn; error bars mean ± SEM by Methods 4.9 — Fig. 5D–F and caption; Results 2.5

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 220127-57-1
Applications Bcr-Abl inhibitor
Formula C29H31N7O.CH4SO3
Molecular Weight 589.7
Synonyms Gleevec; Glivec; CGP-57148B; STI-571
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 101 mg/mL (171.26 mM)
Water 101 mg/mL (171.26 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Imatinib Mesylate Research References

  1. [1] Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer research (2002). PMID: 12154025 Source material
  2. [2] Govaerts I, Prieto C, Vandersmissen C, et al. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. Journal of hematology & oncology (2021). PMID: 34167562 DOI: 10.1186/s13045-021-01114-1 Source material
  3. [3] Kuziel G, Thompson V, D'Amato JV, et al. Stromal CCL2 Signaling Promotes Mammary Tumor Fibrosis through Recruitment of Myeloid-Lineage Cells. Cancers (2020). PMID: 32731354 DOI: 10.3390/cancers12082083 Source material

Publications

2 publications citing this product

  1. Inge Govaerts, .et al. , J Hematol Oncol, 2021, 14: 97 PMID: 34167562
  2. Genevra Kuziel, .et al. , Cancers (Basel), 2020, Jul 28;12(8):E2083 PMID: 32731354

Added to your cart

View Cart Checkout
Loading...